| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 GAAP EPS guidance from $(2.10) to $(1.70) vs $(1.94) analyst estimate..
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.35) to $0.30 vs $(0.35) analyst estimate. Raises FY2025 ...
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0....
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-estab...
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target f...